Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS)
Biomarker
Lower motor neuron (LMN)
Phosphorylated tau (P-tau181)
Plasma
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
09
05
2023
accepted:
15
06
2023
medline:
12
9
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Plasma levels of phosphorylated tau (P-tau181) have been recently reported to be increased in amyotrophic lateral sclerosis (ALS) and associated with lower motor neuron (LMN) impairment. We quantified plasma P-tau181 (pP-tau181) in a cohort of 29 deeply phenotyped ALS patients using the new fully automated Lumipulse assay and analysed phenotype-biomarker correlations. pP-tau181 levels correlated positively with a clinical LMN score (r = 0.3803) and negatively, albeit not significantly, with a composite index of muscle strength (r = - 0.3416; p = 0.0811), but not with Penn Upper Motor Neuron (UMN) Score. Accordingly, pP-tau181 correlated with electromyographic indices of spinal active and chronic denervation (r = 0.4507 and r = 0.3864, respectively) but not with transcranial magnetic stimulation parameters of UMN dysfunction. pP-tau181 levels did not correlate with those in the cerebrospinal fluid (CSF), serum NFL, serum GFAP, CSF/serum albumin ratio, or estimated glomerular filtration rate, but correlated with plasma creatine kinase levels (r = 0.4661). Finally, while not being associated with neuropsychological phenotype, pP-tau181 correlated negatively with pH (r = - 0.5632) and positively with partial pressure of carbon dioxide (PaCO pP-tau181 has potential as ALS biomarker and could be associated with LMN impairment. Its raised levels might reflect pathophysiological processes (tau hyperphosphorylation and/or release) occurring in the axons of LMNs distantly from the CNS and the CSF. pP-tau181 could also be associated with respiratory dysfunction.
Identifiants
pubmed: 37369876
doi: 10.1007/s10072-023-06916-4
pii: 10.1007/s10072-023-06916-4
doi:
Substances chimiques
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3697-3702Informations de copyright
© 2023. Fondazione Società Italiana di Neurologia.
Références
Cousins KAQ, Shaw LM, Shellikeri S et al (2022) Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis. Ann Neurol 92(5):807–818. https://doi.org/10.1002/ana.26462
doi: 10.1002/ana.26462
pubmed: 35877814
Vacchiano V, Mastrangelo A, Zenesini C, Baiardi S, Avoni P, Polischi B, Capellari S, Salvi F, Liguori R, Parchi P, BoReALS group (2023) Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 94(6):428–435. https://doi.org/10.1136/jnnp-2022-330709
doi: 10.1136/jnnp-2022-330709
pubmed: 37012065
Wilson EN, Young CB, Ramos Benitez J et al (2022) Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimers Res Ther 14(1):172. https://doi.org/10.1186/s13195-022-01116-2
doi: 10.1186/s13195-022-01116-2
pubmed: 36371232
pmcid: 9652927
Verde F, Milone I, Colombo E et al (2023) Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis. Front Aging Neurosci 15:1132808. https://doi.org/10.3389/fnagi.2023.1132808
doi: 10.3389/fnagi.2023.1132808
pubmed: 37009451
pmcid: 10050442
Roche JC, Rojas-Garcia R, Scott KM et al (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847–852. https://doi.org/10.1093/brain/awr351
doi: 10.1093/brain/awr351
pubmed: 22271664
pmcid: 3286327
Quinn C, Edmundson C, Dahodwala N, Elman L (2020) Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve 61(4):508–511. https://doi.org/10.1002/mus.26764
doi: 10.1002/mus.26764
pubmed: 31743477
Colombo E, Doretti A, Scheveger F et al (2023) Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis. J Neurol 270(1):511–518. https://doi.org/10.1007/s00415-022-11404-4
doi: 10.1007/s00415-022-11404-4
pubmed: 36183286
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Poletti B, Solca F, Carelli L et al (2016) The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 17(7–8):489–498. https://doi.org/10.1080/21678421.2016.1183679
doi: 10.1080/21678421.2016.1183679
pubmed: 27219526
Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):153–174. https://doi.org/10.1080/21678421.2016.1267768
doi: 10.1080/21678421.2016.1267768
pubmed: 28054827
pmcid: 7409990